Skip to main content
. 2022 Feb 18;13:802671. doi: 10.3389/fmicb.2022.802671

TABLE 2.

IC50 of SMeFM for the propagation of influenza virus clinical isolates.

Strain IC50 (nM)*
A/KANAGAWA/ZC1802/2018 (H1N1pdm09) 32.1 ± 5.0
A/KANAGAWA/AC1877/2019 (H3N2) 23.6 ± 11.2
B/KANAGAWA/AC1807/2019 (Victoria) 60.0 ± 49.2
B/KANAGAWA/IC1740/2018 (Yamagata) 47.8 ± 19.9

*The half-maximal inhibitory concentration (IC50) was determined from the result of the plaque assay. Average values with standard deviations from three independent experiments were shown.